RxDoctor Payments Data

Badie Al Nemr, MD

Infectious Disease · Canton, OHNPI 1497968903

Payments from drug & device makers

$597in general payments, 2019–2025

Across 24 payments — averaging $24.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$165
  • Tetraphase Pharmaceuticals, Inc.$114
  • Paratek Pharmaceuticals, Inc.$101
  • Janssen Products, LP$57
  • Gilead$47
  • Johnson & Johnson$33
  • plus $81 from 5 others

What the payments were for

  • Food & beverage$38565%
  • Education$20434%
  • Gifts$81%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$597 in reported general payments places this provider in the 60th percentile of 308 infectious disease providers in Ohio.

See all infectious disease providers in Ohio

Medicare billing

Part B allowed, 2024
$76,434
Medicare patients
329
Services billed
778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala108$428,719
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf64$355,403
DovatoDolutegravir Sodium/Lamivudine54$157,013
OdefseyEmtricitab/Rilpiviri/Tenof Ala37$145,187
GenvoyaElviteg/Cob/Emtri/Tenof Alafen18$70,129
Daptomycin57$36,384
Vancomycin Hcl139$27,759
ErtapenemErtapenem Sodium31$15,513
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam52$7,912
Fosfomycin Tromethamine23$5,558
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)14$5,382
Cefepime Hcl25$4,966
Darunavir12$4,753
Cefdinir166$4,035
Linezolid23$4,004

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$47$498,848126 claims
Janssen Products, LPSymtuza$57$355,40364 claims
Viiv Healthcare CompanyDovato$165$157,01354 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 308 infectious disease providers in Ohio.

Other infectious disease in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →